inVentiv Health Taps Medidata Enroll to Accelerate Clinical Trials

Medidata, a global provider of cloud-based technology and data analytics for clinical research, and inVentiv Health, a biopharmaceutical professional services company, have just announced a multi-year partnership to bring patient-centric technology and leading clinical trial expertise to the biopharmaceutical industry.

“The partnership will broaden the reach of Medidata’s industry-leading electronic informed consent (eConsent) technology, Medidata Enroll, to patients, sites and biopharmaceutical clients worldwide,” a provided statement explains.

Medidata recently acquired Mytrus, Incorporated, an eClinical technology company specializing in eConsent and virtual trials. inVentiv, an early adopter of eConsent technology, invested in Mytrus in 2013. inVentiv and Medidata will now partner to provide their joint customers with best-in-class training, services and support around the use of the advanced eConsent platform, Medidata Enroll.

“As clinical development evolves toward a more patient-centric, technologically-savvy model, the use of eConsent is becoming increasingly relevant,” said Rachel Stahler, Chief Information Officer, inVentiv Health. “By pairing Medidata’s industry-leading technology platform with inVentiv’s vast clinical trial and patient engagement capabilities, we can expedite study start-up and transform the trial process for patients and sites. This partnership reinforces our commitment to delivering better systems, rich data and actionable insights to accelerate our clients’ abilities to deliver important therapies to market.”

This post was written by:

- who has written 371 posts on mHealthWatch.

Contact the author